MA54538B1 - Inhibiteurs d'apol1 et leurs procédés d'utilisation - Google Patents

Inhibiteurs d'apol1 et leurs procédés d'utilisation

Info

Publication number
MA54538B1
MA54538B1 MA54538A MA54538A MA54538B1 MA 54538 B1 MA54538 B1 MA 54538B1 MA 54538 A MA54538 A MA 54538A MA 54538 A MA54538 A MA 54538A MA 54538 B1 MA54538 B1 MA 54538B1
Authority
MA
Morocco
Prior art keywords
methods
apol1
inhibitors
ndkd
fsgs
Prior art date
Application number
MA54538A
Other languages
English (en)
Other versions
MA54538A (fr
Inventor
Ales Medek
Yi Shi
Muna SHRESTHA
Michael Brodney
Kevin Gagnon
Kan-Nian Hu
Peter Rose
Faith WITKOS
Jingrong Cao
Jon H. Come
Leslie A. DAKIN
Francois Denis
Warren A. DORSCH
Anne FORTIER
Martine Hamel
Elaine B. Krueger
Brian Ledford
Suganthini S. Nanthakumar
Olivier Nicolas
Camil SAYEGH
Timothy J. SENTER
Tiansheng Wang
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of MA54538A publication Critical patent/MA54538A/fr
Publication of MA54538B1 publication Critical patent/MA54538B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne au moins une entité choisie parmi des composés de formule (I), des formes à l'état solide de ceux-ci, des compositions les comprenant, et des procédés d'utilisation de ceux-ci, comprenant l'utilisation dans le traitement de la glomérulosclérose segmentaire focale (FSGS) et/ou d'une maladie rénale non diabétique (NDKD).
MA54538A 2018-12-17 2019-12-17 Inhibiteurs d'apol1 et leurs procédés d'utilisation MA54538B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
EP19839496.7A EP3897833B1 (fr) 2018-12-17 2019-12-17 Inhibiteurs d'apol1 et leurs procédés d'utilisation
PCT/US2019/066746 WO2020131807A1 (fr) 2018-12-17 2019-12-17 Inhibiteurs d'apol1 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA54538A MA54538A (fr) 2021-10-27
MA54538B1 true MA54538B1 (fr) 2026-04-30

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54538A MA54538B1 (fr) 2018-12-17 2019-12-17 Inhibiteurs d'apol1 et leurs procédés d'utilisation

Country Status (35)

Country Link
US (3) US11618746B2 (fr)
EP (2) EP4782443A1 (fr)
JP (1) JP7573528B2 (fr)
KR (2) KR102912203B1 (fr)
CN (1) CN113453760B (fr)
AR (1) AR116913A1 (fr)
AU (1) AU2019405477B2 (fr)
CA (1) CA3121910A1 (fr)
CL (1) CL2021001561A1 (fr)
CO (1) CO2021009053A2 (fr)
CR (1) CR20210383A (fr)
DK (1) DK3897833T3 (fr)
DO (1) DOP2021000116A (fr)
EC (1) ECSP21052184A (fr)
ES (1) ES3067546T3 (fr)
FI (1) FI3897833T3 (fr)
HR (1) HRP20260487T1 (fr)
IL (2) IL319575A (fr)
JO (3) JOP20210131A1 (fr)
LT (1) LT3897833T (fr)
MA (1) MA54538B1 (fr)
MD (1) MD3897833T2 (fr)
MX (1) MX2021007152A (fr)
PE (1) PE20212302A1 (fr)
PL (1) PL3897833T3 (fr)
PT (1) PT3897833T (fr)
RS (1) RS68055B1 (fr)
SA (1) SA521422270B1 (fr)
SG (1) SG11202105769XA (fr)
SI (1) SI3897833T1 (fr)
SM (1) SMT202600169T1 (fr)
TW (1) TWI848031B (fr)
UA (1) UA128375C2 (fr)
UY (1) UY38514A (fr)
WO (1) WO2020131807A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) * 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (fr) * 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leurs méthodes d'utilisation
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (fr) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la glomérulosclérose segmentaire et focale dépendante de l'apol -1
EP4146633A4 (fr) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. Composition destinée à être utilisée dans le traitement d'une maladie associée à apol1
CN115867543A (zh) * 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
JP2023530271A (ja) * 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びこれを使用する方法
US20230014907A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
CA3179178A1 (fr) 2021-02-19 2022-08-25 Maze Therapeutics, Inc. Inhibiteurs d'apol1 et methodes d'utilisation
KR20240051990A (ko) * 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
AU2022401847A1 (en) * 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) * 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023194895A1 (fr) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Dérivés pyrroliques utilisés en tant qu'inhibiteurs de l'apolipoprotéine l-1
US20260055083A1 (en) * 2022-08-19 2026-02-26 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2025006262A1 (fr) * 2023-06-29 2025-01-02 Omniab, Inc. Composés tétracycliques contenant un indole fusionné pour le traitement d'une maladie rénale chronique médiée par apol1
GB202401326D0 (en) * 2024-02-01 2024-03-20 Podium Bio Ltd Novel compounds
KR20250122547A (ko) 2024-02-05 2025-08-14 서주사이언티픽 주식회사 AIoT 기반 방사성 동위원소 관리 시스템
TW202613098A (zh) * 2024-07-09 2026-04-01 大陸商上海旭成醫藥科技有限公司 一種APOLs抑制劑

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
CA2262569A1 (fr) 1996-08-09 1998-02-19 Norihito Ohi Derives de benzopiperidine
EP0924209B1 (fr) 1997-12-19 2003-05-02 Eli Lilly And Company Imidazolines hypoglycémiques
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001017965A2 (fr) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2002028831A1 (fr) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibiteurs de la prenyl-proteine transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
KR20050044450A (ko) 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
WO2003104180A1 (fr) * 2002-06-05 2003-12-18 Natco Pharma Limited Procede de preparation d'acide 4-(4-fluorobenzoyl) butyrique
WO2004058717A1 (fr) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Derives d'isoquinolinone et leur utilisation comme agents therapeutiques
AU2004268919A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders
WO2005092854A1 (fr) 2004-03-03 2005-10-06 Eli Lilly And Company Modulateurs de recepteur nucleaire d'hormones steroides a base de derives indole substitues bicycliques
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
WO2007061763A2 (fr) 2005-11-22 2007-05-31 Merck & Co., Inc. Antagonistes des recepteurs de l’indole orexine
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (fr) 2006-10-16 2009-08-12 Grünenthal GmbH Derives de sulfonamide substitues en tant que modulateurs du recepteur de bradykinine-1
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
PT2118074E (pt) * 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2020414A1 (fr) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose
EP2178870B1 (fr) 2007-08-17 2018-09-19 LG Chem, Ltd. Composés d'indole et d'indazole en tant qu'inhibiteurs de nécrose cellulaire
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
PL2501704T3 (pl) 2009-11-16 2014-02-28 Lilly Co Eli Spiropiperydynowe związki jako antagoniści receptora ORL-1
WO2012025155A1 (fr) 2010-08-26 2012-03-01 Novartis Ag Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) * 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
WO2016029310A1 (fr) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Modulateurs du récepteur cannabinoïde de type 1
BR112017007178A2 (pt) 2014-10-08 2017-12-19 Ass Francaise Contre Les Myopathies compostos de aminopiridina úteis como inibidores de prenilação de proteína
JP2017535545A (ja) 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
HRP20210472T1 (hr) 2015-08-27 2021-05-14 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
CN108884096B (zh) 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
EP3787669A4 (fr) 2018-04-30 2022-03-30 The Trustees of Indiana University Composés destinés à moduler les niveaux de ddah et d'adma, ainsi que leurs méthodes d'utilisation pour traiter une maladie
CN118127019A (zh) 2018-05-22 2024-06-04 Ionis制药公司 Apol1表达的调节剂
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
EP4097083A1 (fr) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leurs méthodes d'utilisation
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (fr) * 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la glomérulosclérose segmentaire et focale dépendante de l'apol -1
CA3171950A1 (fr) 2020-04-22 2021-10-28 David William Sheppard Inhibiteurs de traduction de collagene 1 et leurs procedes d'utilisation
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
EP4146633A4 (fr) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. Composition destinée à être utilisée dans le traitement d'une maladie associée à apol1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2022401847A1 (en) 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
CN119343353A (zh) 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023154314A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Dérivés de spiro pipéridine utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation
EP4476199A1 (fr) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated Dérivés de 2-méthyl-4-phénylpipéridin-4-ol utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation
EP4476228A1 (fr) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated Dérivés de 4',5'-dihydrospiro[pipéridine-4,7'-thiéno[2,3-c]pyran] utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
CN113453760A (zh) 2021-09-28
CA3121910A1 (fr) 2020-06-25
UY38514A (es) 2020-07-31
US12060346B2 (en) 2024-08-13
RS68055B1 (sr) 2026-05-29
EP3897833A1 (fr) 2021-10-27
JOP20210130A1 (ar) 2023-01-30
CR20210383A (es) 2021-09-22
HRP20260487T1 (hr) 2026-05-22
MA54538A (fr) 2021-10-27
CN113453760B (zh) 2024-05-24
UA128375C2 (uk) 2024-06-26
PT3897833T (pt) 2026-04-22
IL283592B1 (en) 2025-04-01
IL283592A (en) 2021-07-29
LT3897833T (lt) 2026-04-27
WO2020131807A1 (fr) 2020-06-25
SA521422270B1 (ar) 2024-02-18
KR20260020195A (ko) 2026-02-10
SMT202600169T1 (it) 2026-05-12
FI3897833T3 (fi) 2026-04-07
ES3067546T3 (en) 2026-05-22
JP7573528B2 (ja) 2024-10-25
AU2019405477A1 (en) 2021-06-24
US11618746B2 (en) 2023-04-04
US20200377479A1 (en) 2020-12-03
AU2019405477B2 (en) 2025-04-03
TWI848031B (zh) 2024-07-11
US20250042878A1 (en) 2025-02-06
EP3897833B1 (fr) 2026-02-04
MX2021007152A (es) 2021-11-03
PL3897833T3 (pl) 2026-06-01
TW202039471A (zh) 2020-11-01
MD3897833T2 (en) 2026-07-31
SG11202105769XA (en) 2021-07-29
CL2021001561A1 (es) 2021-11-26
SI3897833T1 (sl) 2026-05-29
AR116913A1 (es) 2021-06-23
JOP20210129A1 (ar) 2023-01-30
KR102912203B1 (ko) 2026-01-16
PE20212302A1 (es) 2021-12-10
JOP20210131A1 (ar) 2023-01-30
US20230271945A1 (en) 2023-08-31
DOP2021000116A (es) 2021-09-30
ECSP21052184A (es) 2021-08-31
JP2022515369A (ja) 2022-02-18
EP4782443A1 (fr) 2026-07-29
IL319575A (en) 2025-05-01
KR20210116483A (ko) 2021-09-27
BR112021011564A2 (pt) 2021-08-31
IL283592B2 (en) 2025-08-01
DK3897833T3 (da) 2026-03-30
CO2021009053A2 (es) 2021-08-09

Similar Documents

Publication Publication Date Title
SA521422270B1 (ar) Apol1 مثبطات لـ وطرق لاستخدامها
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA51530B1 (fr) Composés cycliques fondus
MA58170B1 (fr) Dérivés carboxy avec des proprietes anti-inflammatoires
JOP20230035A1 (ar) مثبطات apol1 وطرق استخدامها
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA44936A1 (fr) Méthodes de diagnostic et de traitement du cancer
MA52063B1 (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
EP3906043A4 (fr) Procédés et compositions pour le traitement de la maladie de fabry
NO20060825L (no) Imaging Agents
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA29723B1 (fr) Composes
EP4052694A4 (fr) Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
EP3804736A4 (fr) Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu'ingrédient efficace pour la prévention ou le traitement d'une maladie inflammatoire
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
CA3156457A1 (fr) Composes 1,8-naphtyridin-2-one pour le traitement d'une maladie auto-immune
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite